USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
使用 DYRK1A/B 激酶抑制剂治疗肝病
基本信息
- 批准号:10696380
- 负责人:
- 金额:$ 34.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAlzheimer&aposs DiseaseAnimal Disease ModelsAnti-Inflammatory AgentsAntidiabetic DrugsAntioxidantsAreaAttentionBiochemicalBiological AvailabilityBiological MarkersBiological SciencesBody WeightCOL1A1 geneCell ProliferationCellular AssayCirrhosisCollaborationsCollagenCyclin D1CyclodextrinsCytoprotectionDataDepositionDevelopmentDiabetes MellitusDietDisease ProgressionDistressDoseDown SyndromeDrug ExposureDrug KineticsDrug Metabolic DetoxicationDrug TargetingEatingEnhancersExhibitsExtracellular MatrixFABP1 geneFDA approvedFamily memberFatty AcidsFatty LiverFibrosisFormulationFoundationsGenesGlial Fibrillary Acidic ProteinGoalsHalf-LifeHealth PromotionHepaticHepatic Stellate CellHepatotoxicityHigh Fat DietHistologicHypertriglyceridemiaIn VitroInflammationInflammatoryInsulin ResistanceInterferon Type IILeadLiverLiver FibrosisLiver diseasesMeasuresMediatingMetabolic DiseasesModelingMolecular TargetMusNQO1 geneNon-Insulin-Dependent Diabetes MellitusObesityOncologyOralOrganOutcomeOxidation-ReductionPancreasPathologicPathologyPathway interactionsPeripheralPharmaceutical ChemistryPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhasePhase I Clinical TrialsPhosphorylationPhosphotransferasesPioglitazonePlasmaPopulationPrimary carcinoma of the liver cellsProductionProteinsProxyPublic HealthReactive Oxygen SpeciesRegimenResearchRoleRouteSafetySmall Business Innovation Research GrantSpecificitySteatohepatitisStructure of beta Cell of isletTestingTherapeuticTimeToxic effectTranslational ResearchTyrosineTyrosine PhosphorylationVascular Endothelial Growth FactorsVitamin EWorkanimal efficacycell growth regulationchronic liver diseasecombatcytokinedrug mechanismefficacy testingend stage liver diseasefibrogenesisimprovedin vitro activityin vivoinhibitorinnovationinsightinterestkinase inhibitorlipid biosynthesisliver inflammationliver injuryliver transplantationmouse modelnephrotoxicitynervous system disorderneuroinflammationneuronal survivalneuroprotectionnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel therapeuticsnuclear factor-erythroid 2nuclear factors of activated T-cellspharmacokinetics and pharmacodynamicspharmacologicphase 1 studyresponsesafety studysmall molecule inhibitortherapeutic targettranscription factoruptake
项目摘要
PROJECT SUMMARY
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. One-fourth of the adult
population suffers from NAFLD worldwide. Nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD, can
progress to cirrhosis and hepatocellular cancer (HCC) and is rapidly becoming the leading cause of end-stage liver disease
and liver transplantation. Liver fibrosis is a major consequence of chronic liver disease, where the excess extracellular
matrix is deposited, which is caused by the activation of hepatic stellate cells (HSCs). There is an urgent public health need
to develop safe and effective pharmacological treatments to alleviate hepatic inflammation, fibrosis, and steatohepatitis.
However, there are no FDA-approved medications for NAFLD.
This SBIR Phase I proposal seeks to evaluate ABI-171, a novel compound with demonstrated selectivity for
DYRK1A and its close family member DYRK1B in biochemical and cellular assays. ABI-171 exhibits pharmacological
activity with evidence of efficacy in several animal models of disease. We hypothesize that its broad anti-inflammatory and
cytoprotective activities combined with its potential health-promoting activities to thwart diabetes, reduce fatty acid uptake,
and suppress collagen accumulation may effectively combat NAFLD.
In this Phase I study, two specific aims are proposed: in Aim 1 we will evaluate the accumulation of ABI-171 in
the organs of interest, namely the liver, to advance its safety profile. In Aim 2, we will test the efficacy of ABI-171 in the
high-fat diet model of NASH, which is well-established for providing mechanistic insight of treatments and its potential for
research translation. Detailed readouts for this study will be bodyweight and food intake, insulin resistance, liver injury
biomarkers, liver pathology including histological and biochemical assessments, and expression levels of genes and proteins
involved in DYRK1A/1B-mediated regulation of cellular cytoprotection, inflammation, lipogenesis, and fibrogenesis.
The successful completion of this application will significantly advance the efficacy and mechanism of action of
our selective DYRK inhibitor in NASH, thus forming strong foundation for a Phase 2 project in which drug activity will be
examined in more detail for the treatment of metabolic disorders and complete the development work needed to move ABI-
171 into an early-stage clinical trial.
项目摘要
非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝病。四分之一的成年人
全世界的人都患有NAFLD。非酒精性脂肪性肝炎(NASH)是NAFLD的侵袭性形式,
进展为肝硬化和肝细胞癌(HCC),并迅速成为终末期肝病的主要原因
和肝移植。肝纤维化是慢性肝病的主要后果,其中过量的细胞外基质是肝纤维化的主要原因。
基质沉积,这是由肝星状细胞(HSC)活化引起的。公共卫生迫切需要
开发安全有效的药物治疗以减轻肝脏炎症、纤维化和脂肪性肝炎。
然而,没有FDA批准的NAFLD药物。
该SBIR I期提案旨在评估ABI-171,这是一种新型化合物,对
DYRK 1A及其近缘家族成员DYRK 1B在生物化学和细胞测定中的应用。ABI-171具有药理学活性,
在几种动物疾病模型中具有有效性证据的活性。我们假设其广泛的抗炎和
细胞保护活性与其潜在的健康促进活性相结合,以阻止糖尿病,减少脂肪酸摄取,
和抑制胶原蛋白积累可以有效地对抗NAFLD。
在这项I期研究中,提出了两个具体目标:在目标1中,我们将评估ABI-171在
感兴趣的器官,即肝脏,以提高其安全性。在目标2中,我们将测试ABI-171在
NASH的高脂肪饮食模型,其已被充分确立用于提供治疗的机制见解及其治疗的潜力。
研究翻译这项研究的详细读数将是体重和食物摄入量、胰岛素抵抗、肝损伤
生物标志物、肝脏病理学(包括组织学和生物化学评估)以及基因和蛋白质的表达水平
参与DYRK 1A/1B介导的细胞保护、炎症、脂肪生成和纤维生成的调节。
该申请的成功完成将显著提高
我们在NASH中的选择性DYRK抑制剂,从而为2期项目奠定了坚实的基础,其中药物活性将
更详细地检查代谢紊乱的治疗,并完成移动ABI所需的开发工作-
171人进入早期临床试验
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gian Luca Araldi其他文献
Gian Luca Araldi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gian Luca Araldi', 18)}}的其他基金
Development of DYRK1A allosteric modulator for the treatment of Alzheimer’s Disease
开发用于治疗阿尔茨海默病的 DYRK1A 变构调节剂
- 批准号:
9932627 - 财政年份:2019
- 资助金额:
$ 34.92万 - 项目类别:
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease
开发用于治疗阿尔茨海默病的 DYRK1A 变构调节剂
- 批准号:
10708925 - 财政年份:2017
- 资助金额:
$ 34.92万 - 项目类别:
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease
开发用于治疗阿尔茨海默病的 DYRK1A 变构调节剂
- 批准号:
9925159 - 财政年份:2017
- 资助金额:
$ 34.92万 - 项目类别:
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease
开发用于治疗阿尔茨海默病的 DYRK1A 变构调节剂
- 批准号:
10601148 - 财政年份:2017
- 资助金额:
$ 34.92万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 34.92万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 34.92万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 34.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 34.92万 - 项目类别:
Studentship